Trial reportHepatology (Baltimore, Md.)2015
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Trial report in Hepatology (Baltimore, Md.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- KASL clinical practice guidelines: management of hepatitis C.Clinical and molecular hepatology · 2016Guideline
- Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.Journal of translational medicine · 2015Pooled it
- An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.Canadian journal of gastroenterology & hepatologyGuideline
- Hepatitis C virus testing for case identification in persons born during 1945-1965: Results from three randomized controlled trials.Hepatology (Baltimore, Md.) · 2018Trial
- Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6.Journal of clinical microbiology · 2016Trial
- Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).Hepatology (Baltimore, Md.) · 2016Trial
- Article
- Elimination of hepatitis C in the Middle East: a narrative review of the efficacy of direct-acting antiviral therapies.Translational gastroenterology and hepatology · 2025Review
- Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil.World journal of hepatology · 2022Article
- The Bank Vole (Viruses · 2021Article
- Genotype 3-hepatitis C virus' last line of defense.World journal of gastroenterology · 2021Review
- Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.Medicina (Kaunas, Lithuania) · 2018Review
- Article
- Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India.The Indian journal of medical research · 2017Review
- Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions.Current infectious disease reports · 2017Review
- Current therapy for chronic hepatitis C: The role of direct-acting antivirals.Antiviral research · 2017Review
- Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.PloS one · 2017Article
- Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort.Hepatic medicine : evidence and research · 2017Article
- Hepatitis C treatment: where are we now?International journal of general medicine · 2017Review
- Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.The Permanente journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledSofosbuvir (SOF) in combination with ribavirin (RBV) for 12 or 24 weeks is the current standard of care for patients infected with hepatitis C virus (HCV) genotypes 2 and 3, respectively. However, in clinical trials treatment-experienced patients, particularly those with cirrhosis, had suboptimal sustained virological response (SVR) rates. We assessed the efficacy and safety of sofosbuvir plus peginterferon and ribavirin (SOF+Peg-IFN+RBV) administered for 12 weeks to treatment-experienced patients with HCV genotypes 2 and 3, with and without cirrhosis. We enrolled 47 patients in this open-label, nonrandomized, uncontrolled phase 2 study. The primary endpoint was the proportion of patients with SVR at 12 weeks after cessation of study treatment (SVR12). The overall rate of SVR12 was 89% (95% confidence interval [CI]: 77-97). Rates of SVR12 were higher in patients with genotype 2 than in those with genotype 3, 96% (95% CI: 78-100) and 83% (95% CI: 62-95), respectively. Rates of SVR12 were similar in patients with and without cirrhosis: for genotype 2, 93% of patients with cirrhosis and 100% of patients without cirrhosis achieved SVR12, and for genotype 3, the SVR12 rate was 83% in patients both with and without cirrhosis. One patient discontinued study treatment because of an adverse event and four patients experienced serious adverse events. The most common adverse events were influenza-like illness, fatigue, anemia, and neutropenia.
conclusionIn treatment-experienced patients with HCV genotypes 2 and 3, 12-week administration of SOF+Peg-IFN+RBV provided high SVR rates, irrespective of cirrhosis status. No safety concerns were identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.